Biotech Micreos appoints CMO to lead clinical development of antibiotic alternative
pharmafile | March 23, 2016 | Appointment | Research and Development |
Dr Johan Frieling has been appointed as the new chief medical officer of Dutch biotech company Micreos, at a pivotal time in the company’s history as it prepares for clinical trials with Staphefekt, an antibiotic alternative.
Dr Frieling is a seasoned biopharmaceutical industry professional who acquired a wealth of clinical development experience during over a period of more than 20 years. He held positions at pharmaceutical giant Bayer and biotech pioneer Genzyme, and most recently served as head of Global Clinical Research at LFB Biotechnologies.
He joins at an exciting time for Micreos, with the company having recently secured €12 million funding for clinical development of its antibiotic alternative, Staphefekt, into a pharmaceutical (Rx) product in several indications, including atopic dermatitis.
“Johan has successfully developed a number of biopharmaceutical products up to FDA and EMA approval. For us he is the ideal person to lead Staphefekt to market in the new indications.” says Mark Offerhaus, founder and chief executive of Micreos.
Dr Frieling says: “It’s a great time to be joining Micreos. Many people with inflammatory skin conditions like eczema, rosacea and acne are already benefiting from Staphefekt. This helps us to design the right clinical trials for new indications. I look forward to sharing my knowledge and leading the clinical development of Staphefekt, ultimately helping a large cohort of patients across the globe.”
Dr Frieling has a medical degree, as well as a PhD in Medical Sciences from the University of Nijmegen. He has authored many academic publications for various prestigious journals, and has presented his work at global congresses of the highest calibre in their field.
